Literature DB >> 22202179

Chemokines and cytokines in patients with an occult Onchocerca volvulus infection.

Christian J Lechner1, Richard G Gantin, Tanja Seeger, Alicja Sarnecka, Jennifer Portillo, Hartwig Schulz-Key, Potochoziou K Karabou, Gertrud Helling-Giese, Christoph Heuschkel, Meba Banla, Peter T Soboslay.   

Abstract

Repeated ivermectin treatment will clear microfilaria (Mf) of Onchocerca volvulus from skin and eyes of onchocerciasis patients while adult filaria remains alive and reproductive, and such occult O. volvulus infection may persist for years. To investigate the effect of residual adult filaria on the immune response profile, chemokines and cytokines were quantified 1) in onchocerciasis patients who developed an occult O. volvulus infection (Mf-negative) due to repeated ivermectin treatments, 2) patients who became Mf-negative without ivermectin treatments due to missing re-infection, and 3) endemic and non-endemic O. volvulus Mf-negative controls. With occult O. volvulus infection, serum levels of pro-inflammatory chemokines MCP-1/CCL2, MIP-1α/CCL3, MIP-1β/CCL4, MPIF-1/CCL23 and CXCL8/IL-8 enhanced and approached higher concentrations as determined in infection-free controls, whilst regulatory and Th2-type cytokines and chemokines MCP-4/CCL13, MIP-1δ/CCL15, TARC/CCL17 and IL-13 lessened. Levels of Eotaxin-2/CCL24, MCP-3/CCL7 and BCA-1/CXCL13 remained unchanged. At 3 days post-initial ivermectin treatment, MCP-1/CCL2, MCP-4/CCL13, MPIF-1/CCL23 and Eotaxin-2/CCL24 were strongly enhanced, suggesting that monocytes and eosinophil granulocytes have mediated Mf clearance. In summary, with occult and expiring O. volvulus infections the serum levels of inflammatory chemokines enhanced over time while regulatory and Th2-type-promoting cytokines and chemokines lessened; these changes may reflect a decreasing effector cell activation against Mf of O. volvulus, and in parallel, an enhancing inflammatory immune responsiveness.
Copyright © 2011 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22202179     DOI: 10.1016/j.micinf.2011.12.002

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  12 in total

1.  Baseline characterization of epilepsy in an onchocerciasis endemic area of the Democratic Republic of Congo.

Authors:  Kevin G Burfeind; Jean-Marie K Kashama; Béatrice K Bora; Charles F Murchison; Ana L Ramos-Crawford; Mambulu T Nseka; Shako B Kunyu; Daniel L Okitundu; Nicole L Mashukano; Jean-Pierre M Banea; J Boivin Michael; Jean-Claude K Mwanza; Dieudonne Mumba; Desire D Tshala-Katumbay
Journal:  Brain Res Bull       Date:  2018-11-20       Impact factor: 4.077

2.  Cytokine and chemokine responses to helminth and protozoan parasites and to fungus and mite allergens in neonates, children, adults, and the elderly.

Authors:  Christian J Lechner; Karl Komander; Jana Hegewald; Xiangsheng Huang; Richard G Gantin; Peter T Soboslay; Abram Agossou; Meba Banla; Carsten Köhler
Journal:  Immun Ageing       Date:  2013-07-15       Impact factor: 6.400

3.  Onchocerca volvulus-specific antibody and cellular responses in onchocerciasis patients treated annually with ivermectin for 30 years and exposed to parasite transmission in central Togo.

Authors:  Saskia I Johanns; Richard G Gantin; Bawoubadi Wangala; Kossi Komlan; Wemboo A Halatoko; Meba Banla; Potchoziou Karabou; Adrian Jf Luty; Hartwig Schulz-Key; Carsten Köhler; Peter T Soboslay
Journal:  PLoS Negl Trop Dis       Date:  2022-05-03

4.  Reductions in microfilaridermia by repeated ivermectin treatment are associated with lower Plasmodium-specific Th17 immune responses in Onchocerca volvulus-infected individuals.

Authors:  Kathrin Arndts; Ute Klarmann-Schulz; Linda Batsa; Alexander Y Debrah; Christian Epp; Rolf Fimmers; Sabine Specht; Laura E Layland; Achim Hoerauf
Journal:  Parasit Vectors       Date:  2015-03-28       Impact factor: 3.876

5.  Elevated Plasma Chemokines for Eosinophils in Neuromyelitis Optica Spectrum Disorders during Remission.

Authors:  Yanping Tong; Tao Yang; Jingwen Wang; Tianyou Zhao; Lei Wang; Yuezhi Kang; Cuicui Cheng; Yongping Fan
Journal:  Front Neurol       Date:  2018-02-12       Impact factor: 4.003

6.  Onchocerca volvulus infection and serological prevalence, ocular onchocerciasis and parasite transmission in northern and central Togo after decades of Simulium damnosum s.l. vector control and mass drug administration of ivermectin.

Authors:  Kossi Komlan; Patrick S Vossberg; Richard G Gantin; Tchalim Solim; Francois Korbmacher; Méba Banla; Koffi Padjoudoum; Potchoziou Karabou; Carsten Köhler; Peter T Soboslay
Journal:  PLoS Negl Trop Dis       Date:  2018-03-01

7.  Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study.

Authors:  Suzan M Mansour; Rehab N Shamma; Kawkab A Ahmed; Nirmeen A Sabry; Gamal Esmat; Azza A Mahmoud; Amr Maged
Journal:  Int Immunopharmacol       Date:  2021-07-23       Impact factor: 4.932

8.  Immunoepidemiological profiling of onchocerciasis patients reveals associations with microfilaria loads and ivermectin intake on both individual and community levels.

Authors:  Kathrin Arndts; Sabine Specht; Alexander Y Debrah; Francesca Tamarozzi; Ute Klarmann Schulz; Sabine Mand; Linda Batsa; Alexander Kwarteng; Mark Taylor; Ohene Adjei; Coralie Martin; Laura E Layland; Achim Hoerauf
Journal:  PLoS Negl Trop Dis       Date:  2014-02-20

9.  The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice.

Authors:  Jessica A Hess; Bin Zhan; April R Torigian; John B Patton; Nikolai Petrovsky; Tingting Zhan; Maria Elena Bottazzi; Peter J Hotez; Thomas R Klei; Sara Lustigman; David Abraham
Journal:  PLoS Negl Trop Dis       Date:  2016-07-07

10.  Mansonella perstans, Onchocerca volvulus and Strongyloides stercoralis infections in rural populations in central and southern Togo.

Authors:  Francois Korbmacher; Kossi Komlan; Richard G Gantin; Wiyao P Poutouli; Koffi Padjoudoum; Potchoziou Karabou; Peter T Soboslay; Carsten Köhler
Journal:  Parasite Epidemiol Control       Date:  2018-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.